Join to view full profile
1 Barnes Jewish Hospital Plz# DivSt. Louis, MO 63110
Phone+1 314-362-5641
Fax+1 314-362-0369
Dr. Duncavage is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Utah HealthFellowship, Hematopathology, 2009 - 2010
Washington University/B-JH/SLCH ConsortiumFellowship, Molecular Genetic Pathology, 2008 - 2009- Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 2004 - 2008
University of Tennessee Health Science Center College of MedicineClass of 2004
Certifications & Licensure
IL State Medical License 2014 - 2029
MO State Medical License 2007 - 2027
UT State Medical License 2009 - 2012
American Board of Pathology Pathology - Anatomic/Pathology - Clinical- American Board of Pathology Clinical Informatics
- American Board of Pathology Pathology - Molecular Genetic
- American Board of Pathology Hematopathology
Publications & Presentations
PubMed
- Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.Meagan A Jacoby, David H Spencer, Feng Gao, Geoffrey L Uy, Tasha Burton
NEJM Evidence. 2026-09-01 - Validation of a tissue-based predictive RNA test for immunotherapy benefit in NSCLC: the PREDAPT study.Kevin C Flanagan, Jon Earls, Jeffrey Hiken, Rachel L Wellinghoff, Michelle M Ponder
NPJ Precision Oncology. 2026-07-29 - Unique characteristics of Lynch syndrome-associated mismatch repair-deficient colorectal intramucosal carcinoma.Jiannan Li, Andrew E O Hughes, Tianjiao Wang, Kathleen Byrnes, Eric J Duncavage
American Journal of Clinical Pathology. 2026-07-06
Journal Articles
- TP53 Immunohistochemistry Correlates TP53 Mutation Status and Clearance in Decitabine-Treated Patients with Myeloid MalignanciesJohn S Welch, Eric J Duncavage, Haematologica
- Exome Analysis of Treatment‐Related AML After APL Suggests Secondary EvolutionJohn S Welch, Eric J Duncavage, Meagan A Jacoby, Peter Westervelt, Lukas D Wartman, British Journal of Haematology
- Discriminating a Common Somatic ASXL1 Mutation (c.1934dup; p.G646Wfs*12) from Artifact in Myeloid Malignancies Using NGSJonathan W Heusel, Richard D Press, Matthew J Walter, Eric J Duncavage, Nature
Press Mentions
Birthplace of Precision MedicineNovember 14th, 2024- Cofactor Genomics Publishes Clinical Validation of OncoPrism-HNSCC, a Test Leveraging Novel RNA Modeling Technology to Predict Response to ImmunotherapyNovember 7th, 2024
- As Use of Large Cancer Panels and Whole-Genome Sequencing Expands, Illumina Plans to Future-Proof NGS Interpretation and ReportingMarch 28th, 2023
Grant Support
- Whole Genome Sequencing for Genomic Evaluation and Risk Stratification of Patients with Myelodysplastic SyndromesWASHINGTON UNIVERSITY2022–2028
- A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung CancerWASHINGTON UNIVERSITY2023–2026
- Genome sequencing for evaluating the efficacy, specificity, and safety of human genome editingWASHINGTON UNIVERSITY2023–2026
- Whole Genome Sequencing for Genomic Evaluation and Risk Stratification of Patients with Myelodysplastic SyndromesWASHINGTON UNIVERSITY2022–2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: